Loading...
Although nonalcoholic steatohepatitis (NASH) is prevalent, there is no approved pharmacologic treatment for this condition. Elafibranor is an agonist of the peroxisome proliferator–activated receptor-alpha and receptor-gamma that play key roles in fatty acid transport, oxidation, glucose homeostasis, and anti-inflammatory activities. This phase II international, randomized, placebo-controlled, multicenter study evaluated the efficacy of elafibranor for treating NASH. A total of 276 patients with biopsy-proven NASH but not cirrhosis were randomized to elafibranor 80 mg, elafibranor 120 mg, or placebo. Patients were followed every 2 months for a year, and an end-of-treatment biopsy was performed.
There was no difference between the elafibranor…